» Articles » PMID: 14654265

Anemia at the End of Life: Prevalence, Significance, and Causes in Patients Receiving Palliative Care

Overview
Publisher Elsevier
Date 2003 Dec 5
PMID 14654265
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

While data exist on the prevalence and causes of anemia in defined groups of the elderly, information on palliative care patients is limited. Compared to actively treated oncology patients, for whom anemia treatment has demonstrated improved quality of life and symptom alleviation, studies of treatment outcomes in palliative care patients are limited. Knowledge of the extent and causes of anemia in palliative care patients is needed, as correction of anemia in these patients could potentially improve their physical, emotional, and cognitive functioning. In the present study, clinical data and blood test results of 105 patients meeting specific eligibility criteria were examined to estimate the prevalence of anemia and investigate its causes. Ninety-five (90.5%) patients had advanced cancer. Based on World Health Organization criteria, anemia was found in 77% of men (Hb <130 g/l) and 68.2% of women (Hb <120 g/l). The diagnosis was anemia of chronic disease in 76.7% of women and 46.8% of men. Patients with prostate cancer had a significantly lower mean Hb level (P=0.007) and more evidence of bone metastases (P=0.0007) than those with other cancers. Neutrophil hypersegmentation, suggesting occult folate deficiency, was present in 28.6% of patients, being more common in those with major weight loss (58.3%) than those with moderate (37%) or mild/no weight loss (26%) (P=0.019). The findings suggest that anemia is highly prevalent in the palliative care setting. Although anemia of chronic disease is most common, occult folate deficiency may be more prevalent than previously suspected. The findings suggest that a low serum folate level is an insensitive marker of occult folate deficiency. A randomized controlled trial of folic acid treatment is proposed.

Citing Articles

Restrictive Blood Transfusion Policy for the Management of Anemia in Palliative Care in Finland.

Poyhia R, Hamalainen S, Neoh K, Lamminmaki A Palliat Med Rep. 2025; 5(1):578-584.

PMID: 40007691 PMC: 11848061. DOI: 10.1089/pmr.2024.0050.


Investigation and management of iron deficiency anaemia in a specialist palliative care setting and the role of intravenous iron: a descriptive analysis of hospice data.

Steele T, Bonwick H, Nwosu A, Chapman L AMRC Open Res. 2024; 3:6.

PMID: 38708071 PMC: 11064982. DOI: 10.12688/amrcopenres.12963.2.


Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021.

Lancet Haematol. 2023; 10(9):e713-e734.

PMID: 37536353 PMC: 10465717. DOI: 10.1016/S2352-3026(23)00160-6.


Transfusion practices in patients with advanced cancer: a retrospective study in a palliative care service.

Marote S, Marinho J, Silva M, Ferraz Goncalves J Porto Biomed J. 2023; 7(6):e195.

PMID: 37152079 PMC: 10158856. DOI: 10.1097/j.pbj.0000000000000195.


The ICaRAS randomised controlled trial: Intravenous iron to treat anaemia in people with advanced cancer - feasibility of recruitment, intervention and delivery.

Dickson E, Ng O, Keeler B, Wilcock A, Brookes M, Acheson A Palliat Med. 2023; 37(3):372-383.

PMID: 36609173 PMC: 10021128. DOI: 10.1177/02692163221145604.